Palvella Therapeutics is no longer a Phase 3 story. The Wayne, Pennsylvania company completed a rolling new-drug application for its topical rapamycin gel in microcystic lymphatic malformations at the end of August, after a single-arm late-stage study posted statistically significant gains on every pre-specified efficacy measure. The equity now prices a first-in-disease rare-dermatology launch more than it prices residual trial risk. The open debate is whether the Food and Drug Administration accepts that baseline-controlled package under Breakthrough Therapy and Fast Track designations, and whether Priority Review follows.
The February equity raise filled the balance sheet and funded a larger commercial and medical-affairs build than management first sketched. Mid-year cash and investments sit near $251 million. Full-year cash spend is guided at $85 million to $95 million. That liquidity covers the planned launch window without another forced raise. Ligand still holds a high-single-digit royalty on worldwide product sales, and operating expense more than doubled as manufacturing, the application, and headcount all scaled together. The cash is real optionality. The royalty is a permanent claim on whatever franchise that cash is trying to build.
Second-quarter operating expense rose to $21 million from $9 million a year earlier as the application and launch prep arrived together. The market value near $2 billion already treats approval as the base case. The next test is whether the agency files the application and grants Priority Review, or whether a refuse-to-file letter or a standard review clock forces the equity to reprice the launch year.